THE FOUR QUESTIONS
01
Every comparable SBIR/STTR award (R43, R44, R41, R42) pulled from NIH RePORTER, totaled, and trended. For the sample technology: six awards, and the curve steepens sharply into FY2025.
FUNDING TREND · COMPARABLE AWARDS, FY2022–2025
TOTAL $5,210,000 · 6 AWARDS▲ TREND ACCELERATING
NIH INSTITUTES & CENTERS · RANKED BY DOLLARS AWARDED
3 AWARDS
2 AWARDS
1 AWARD
02
Not "NIH." The specific Institute or Center that writes the checks in your space, ranked by dollars. Your application gets pointed where the money already moves, and written in that Institute's language.
03
The companies and principal investigators in your lane: the work your application will be judged against, and the collaborators you haven't met yet. In the sample landscape, one PI holds funded awards at two different companies.
FUNDED ORGANIZATIONS & ACTIVE PIs · SAMPLE LANDSCAPE
OKAFOR, A. HOLDS FUNDED AWARDS AT TWO COMPANIES. COLLABORATOR OR COMPETITOR · EITHER WAY, A NAME YOU SHOULD KNOW.
04
Open HHS solicitations from SBIR.gov, matched to your technology by topic, with the deadlines you can still hit. No expired program announcements, no manual trawling.
05 · THE HARDEST PAGE
The single most important page of an NIH application, patterned on the abstracts that actually got funded and tuned to the recommended Institute. Placeholders stay visibly bracketed. GrantScope does not fabricate preliminary results.
SPECIFIC AIMS · DRAFT v0.1 · PATTERNED ON 6 FUNDED ABSTRACTS · TUNED TO NIDDK
[COMPANY] will develop an ionizable lipid nanoparticle (LNP) platform for hepatocyte-directed delivery of mRNA encoding [ENZYME], to treat [RARE INHERITED METABOLIC DISEASE]. An estimated [N] U.S. patients have no disease-modifying option; enzyme replacement does not reach the hepatic compartment where pathology originates.
Aim 1. Formulate and screen. Synthesize a focused ionizable lipid library and screen LNP candidates for hepatocyte tropism, selecting a lead that achieves [≥X]-fold expression over benchmark in [MODEL].
Aim 2. Establish durability and tolerability. Characterize expression kinetics and repeat-dose tolerability of the lead formulation in [MURINE MODEL] against pre-registered go/no-go criteria.
Aim 3. De-risk manufacture. Demonstrate microfluidic batch reproducibility at [SCALE], establishing the CMC baseline a Phase II continuation will require.
A FIRST DRAFT TUNED TO THE FUNDED RECORD · FOR THE PI TO FINISH.
06 · WHAT YOU KEEP
The branded PDF report
The document you circulate: to your co-founder, your advisor, your tech-transfer office.
GrantScope Alerts <alerts@pixkanaka.com>
New in your space: 1 award, 1 solicitation
R44 · $1,400,000 · NIAID · Scalable LNP manufacturing platform, Phase II continuation
Solicitation · NIDDK Rare Metabolic Disease Therapies · closes Jul 20, 2026
YOU'RE WATCHING: LNP mRNA DELIVERY · WEEKLY DIFF · UNSUBSCRIBE ANYTIME
Email alerts
Save the search. When a new award or solicitation appears in your space, you hear about it first.
07 · WHERE IT SITS
Every number GrantScope reports comes from NIH RePORTER and SBIR.gov · free, public, unauthenticated federal data. The read is free too; what a working relationship adds is the analysis, the targeting, and the strategy.
ENTERPRISE INTELLIGENCE
Citeline- and Cortellis-class platforms
Excellent and comprehensive, built for pharma portfolio strategy, with licensing priced to match.
FIVE FIGURES / SEAT / YEAR
GRANT CONSULTANTS
Hands-on proposal services
Useful hands on a full application. The landscape analysis is typically a small fraction of a multi-week engagement.
$5–15K / PROPOSAL
● GRANTSCOPE
The same federal record, read systematically
Landscape, Institute targeting, funded competitors, open deadlines, and a Specific Aims first draft · in one session.
FREE · THE READ + SPECIFIC AIMS DRAFT + PDF
A CONVERSATION · THE VERIFIED LANDSCAPE + STRATEGY
NO DATA LICENSE · NO SEAT MINIMUM · NO SIGN-UP · NO AWARD PROMISES
PIXKANAKA VENTURES
GrantScope is the free funding-intelligence instrument of Pixkanaka Ventures, a life-science business-development practice. It is run by Eric Merle, Principal of Pixkanaka Ventures: doctoral training in molecular cell biology, global biotech and healthtech commercialization, French Foreign Trade Advisor and Chair of the Life Sciences chapter for North America.
THE ONE PROMISE WE WON'T MAKE
GrantScope targets and de-risks your application and accelerates the first draft. It never promises an award. Outcomes depend on your science and on peer review, as they should.
ONE SESSION · YOUR TECHNOLOGY · A LANDSCAPE YOU KEEP